I have used three payment routes and the only thing that changed with each was how much leverage I had when something went wrong.
What I actually want to know is how people are thinking about the trade-off between reversibility and privacy, because you cannot have both.
Practical detail welcome, however dull — the duller the better.
This one has a reasonably settled answer, so here it is. There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
NurseKim_ATL said:There is a difference between no evidence and evidence of no effect, and this subject is one where the two get swapped freely in both directions.
No disagreement, though the timescale matters more than the mechanism here. Most of what looks like a difference in kind turns out to be a difference in how long somebody waited.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View Resultsemma_london said:I have used three payment routes and the only thing that changed with each was how much leverage I had when something went wrong.
This is my experience too, for whatever a second data point is worth. I had assumed I was the exception until I read this.
Adding the clinical framing, because it changes how the question reads. If two explanations both fit, the useful question is which one predicts something the other does not. That is answerable; arguing about which sounds more plausible is not.